Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3629-3634

  Walker, Evan J ^a   Simko, Jeffry P ^b   Ko, Andrew H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gastrointestinal stromal cell tumor (GIST); Hepatitis B; Imatinib; Reactivation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 7; CD34 ANTIGEN; ENTECAVIR; FRESH FROZEN PLASMA; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMATINIB; MYCOPHENOLIC ACID; PREDNISONE; STEM CELL FACTOR RECEPTOR; TACROLIMUS; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CANCER THERAPY; CASE REPORT; CHOLESTASIS; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS HEMODIALYSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; FINE NEEDLE ASPIRATION BIOPSY; FULMINANT HEPATIC FAILURE; GASTROINTESTINAL STROMAL TUMOR; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; LIVER CELL; LIVER GRAFT; LIVING DONOR; MALE; MONOTHERAPY; PRACTICE GUIDELINE; RECURRENCE RISK; RISK FACTOR; SCREENING; TUMOR VOLUME; VIRUS REACTIVATION; WEDGE RESECTION; ACUTE LIVER FAILURE; ADJUVANT CHEMOTHERAPY; DRUG EFFECT; GASTROINTESTINAL STROMAL CELL TUMOR (GIST); GASTROINTESTINAL TUMOR; HEPATITIS B VIRUS; LIVER TRANSPLANTATION; MIDDLE AGED; PHYSIOLOGY; REACTIVATION; VIROLOGY; VIRUS ACTIVATION;

GASTROINTESTINAL STROMAL CELL TUMOR (GIST); HEPATITIS B; IMATINIB; REACTIVATION;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMOTHERAPY, ADJUVANT; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HEPATITIS B VIRUS; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; VIRUS ACTIVATION;

EID: 84906315458     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK and Todd D: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100: 182-188, 1991.
2. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B and Johnson PJ: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62: 299-307, 2000.
3. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM and Ward JW: Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57: 1-20, 2008.
4. Miettinen M and Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70-83, 2006.
5. Nakamura Y, Motokura T, Fujita A, Yamashita T and Ogata E: Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 78: 2210-2215, 1996.
6. Perrillo RP: Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120: 1009-1022, 2001.
7. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B and Kuriyan J: Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase. Science 289: 1938-1942, 2000.
8. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932, 2000.
9. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl Protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
10. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD and Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.
11. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ and Borden EC: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26: 626-632, 2008.
12. Nilsson B, Sjölund K, Kindblom L-G, Meis-Kindblom JM, Bümming P, Nilsson O, Andersson J and Ahlman H: Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 96: 1656-1658, 2007.
13. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR and Owzar K: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373: 1097-1104, 2009.
14. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S,Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvega˚rd T and Reichardt P: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307: 1265-1272, 2012.
15. Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, Noji H, Ogawa K, Nakamura A, Ohira H, Sato Y and Maruyama Y: Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 47: 155-157, 2006.
16. Thia TJK, Tan HH, Chuah THC, Chow WC and Lui HF: Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J 49: e86-89, 2008.
17. Kang BW, Lee SJ, Moon JH, Kim S-N, Chae YS, Kim JG, Hwang YJ and Sohn SK: Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 90: 383-387, 2009.
18. Kim SG, Chun JM, Jin R, Kim JY, Won DI and Hwang YJ: Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc 42: 843-845, 2010.
19. Wang Y-D, Cui G-H, Li M, Gowrea B, Xia J and Hu Y: Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J 125: 2636-2637, 2012.
20. Lai G-M, Yan S-L, Chang C-S and Tsai C-Y: Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 19: 1318-1321, 2013.
21. Lakhani S, Davidson L, Priebat DA and Sherker AH: Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatol Int 2: 498-499, 2008.
22. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M and Morra E: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645-652, 2002.
23. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP and Lockhart DJ: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336, 2005.
24. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR and Vuk-Pavlovic S: Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo . Blood 104: 1094-1099, 2004.
25. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV and Dazzi F: Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18: 1332-1339, 2004.
26. Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE and Wiestner A: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dosedependent manner. Blood 105: 2473-2479, 2005.
27. + regulatory T cells in a dose-dependent manner. Int J Oncol 31: 1133-1139, 2007.
28. + peripheral blood progenitor cells. Blood 103: 538-544, 2004.
29. Daniels JMA, Vonk-Noordegraaf A, Janssen JJWM, Postmus PE and van Altena R: Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J 33: 670-672, 2009.
30. Speletas M, Vyzantiadis T-A, Kalala F, Plastiras D, Kokoviadou K, Antoniadis A and Korantzis I: Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment. Med Mycol 46: 259-263, 2008.
31. Bekkenk MW, Vermeer MH, Meijer CJ, Jansen PM, Middeldorp JM, Stevens SJ and Willemze R: EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood 102: 4243-4243, 2003.
32. Leguay T, Foucaud C, Parrens M, Fitoussi O, Bouabdallah K, Belaud-Rotureau MA, Tabrizi R, Marit G, Pigneux A and Milpied N: EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia. Leukemia 21: 2208-2210, 2007.
33. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A and Kantarjian HM: Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 9: 976-980, 2003.
34. Durosinmi MA, Ogbe PO, Salawu L and Oyekunle AA: Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour. Singapore Med J 48: e16-18, 2007.
35. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A,Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L and Larson RA: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006.
36. Kumar M, Jain S, Sharma BC and Sarin SK: Differentiating acute hepatitis B from the first episode of symptomatic exacerbation of chronic hepatitis B. Dig Dis Sci 51: 594-599, 2006.
37. Yeo W and Johnson PJ: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43: 209-220, 2006.
38. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F and Csako G: Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148: 519-528, 2008.
39. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, Zon RT and Wong SL: American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening inpatients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28: 3199-3202, 2010.
40. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD and Zalcberg J: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw 5(Suppl 2): S1-29, 2007.
41. National Comprehensive Cancer Network. Chronic Myelogenous Leukemia NCCN Guidelines (Version 3.2014). http://www.nccn.org/professionals/physician-gls/pdf/cml.pdf. Accessed February 13, 2014.